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3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are widely used
for secondary stroke prevention. Besides their lipid-lowering activity, pleiotropic effects on
neuronal survival, angiogenesis, and neurogenesis have been described. In view of these
observations, we were interested whether HMG-CoA reductase inhibition in the post-acute
stroke phase promotes neurological recovery, peri-lesional, and contralesional neuronal
plasticity. We examined effects of the HMG-CoA reductase inhibitor rosuvastatin (0.2 or
2.0 mg/kg/day i.c.v.), administered starting 3 days after 30 min of middle cerebral artery
occlusion for 30 days. Here, we show that rosuvastatin treatment significantly increased
the grip strength and motor coordination of animals, promoted exploration behavior, and
reduced anxiety. It was associated with structural remodeling of peri-lesional brain tis-
sue, reflected by increased neuronal survival, enhanced capillary density, and reduced
striatal and corpus callosum atrophy. Increased sprouting of contralesional pyramidal tract
fibers crossing the midline in order to innervate the ipsilesional red nucleus was noticed
in rosuvastatin compared with vehicle-treated mice, as shown by anterograde tract tracing
experiments. Western blot analysis revealed that the abundance of HMG-CoA reductase
was increased in the contralesional hemisphere at 14 and 28 days post-ischemia. Our
data support the idea that HMG-CoA reductase inhibition promotes brain remodeling and
plasticity far beyond the acute stroke phase, resulting in neurological recovery.
Keywords: middle cerebral artery occlusion, neurological recovery, neuronal plasticity, restorative therapy, statin,
tract tracing
INTRODUCTION
Major efforts have been made in recent years to promote
stroke recovery by stimulation of axonal sprouting (Hermann
and Chopp, 2012). A variety of strategies have been used for
this purpose. Antibodies aiming at the neutralization of axonal
growth inhibitors [e.g., Nogo-A (Papadopoulos et al., 2002;
Wiessner et al., 2003)], pleiotropic growth factors [e.g., ery-
thropoietin, vascular endothelial growth factor (Reitmeir et al.,
2011, 2012)], and neural precursor/stem cells (Bacigaluppi et al.,
2009; Andres et al., 2011) have been administered. These treat-
ments are not easily transferrable to human patients due to the
inexistence of systemic delivery strategies and/or potential side
effects and complications that endanger therapeutic success [e.g.,
brain inflammation in case of antibodies targeting CNS epi-
topes (Orgogozo et al., 2003) or malignant transformation in
case of cell-based therapies (Amariglio et al., 2009)]. Hence, the
clinical translation of plasticity-promoting therapies is still on
the way.
Following the stroke prevention by aggressive reduction in
cholesterol levels trial (Amarenco et al., 2006), 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors
(also called statins) are widely used for secondary stroke pre-
vention. Besides their cholesterol-lowering properties, HMG-CoA
reductase inhibitors exert pleiotropic effects in the brain that are
beneficial for stroke recovery, promoting post-ischemic neuronal
survival (Sironi et al., 2003; Kilic et al., 2005), inhibiting inflam-
matory responses (Pahan et al., 1997; Kilic et al., 2005), restoring
endothelial function (Endres et al., 1998; Amin-Hanjani et al.,
2001), and promoting angiogenesis and neurogenesis (Chen et al.,
2003).
Based on these multiple observations, we now examined if
HMG-CoA reductase inhibition influences neurological recov-
ery and brain plasticity in the post-acute stroke phase. Thus,
we exposed mice to intraluminal middle cerebral artery occlu-
sion (MCAO) and investigated effects of the HMG-CoA reductase
inhibitor rosuvastatin, administered starting 3 days post-ischemia
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(dpi), on functional neurological recovery, peri-lesional brain
remodeling, and contralesional pyramidal tract plasticity.
MATERIALS AND METHODS
EXPERIMENTAL GROUPS AND INTERVENTIONS
Experiments were performed using male C57Bl6/j mice (23–25 g)
in accordance to National Institutes of Health Guidelines for
the Care and Use of Laboratory Animals with local government
approval (Istanbul Medipol University, Turkey). A total of four sets
of mice were examined:
The first set of mice was exposed to 30 min of left-sided MCAO.
At 72 h post-ischemia, animals received implantations of cannula
connected to miniosmotic pumps (Alzet 2004; Alzet, Cupertino,
CA, USA) into the left lateral ventricle that were randomly filled
with vehicle (0.9% NaCl) or rosuvastatin (0.2 or 2 mg/kg/day
diluted in 0.9% NaCl) (n= 10 animals/group). These miniosmotic
pumps were left in place during the subsequent 4 weeks and then
removed. At 42 dpi, animals were sacrificed by transcardiac per-
fusion with 0.9% NaCl. These animals were used for functional
neurological studies and conventional histochemistry (Figure S1A
in Supplementary Material).
The second set of mice was subjected to 30 min MCAO, fol-
lowed by implantation of miniosmotic pumps filled with vehicle
or rosuvastatin (0.2 or 2 mg/kg/day) 72 h later using the same
protocol (n= 10 animals/group). The miniosmotic pumps were
again left in place for 4 weeks and then removed. At 42 dpi, animals
were sacrificed by transcardiac perfusion with 4% paraformalde-
hyde. These animals were used for functional neurological stud-
ies, computer-based stereology, and volumetry (Figure S1B in
Supplementary Material).
The third set of mice was submitted to 30 min of MCAO or
sham-surgery, following by implantation of miniosmotic pumps
filled with vehicle or rosuvastatin (2 mg/kg/day) 72 h later using
the same protocol (n= 10 animals/group). The miniosmotic
pumps were again left in place for 4 weeks and then removed.
The animals were used for functional neurological studies and
anterograde tract tracing. For this purpose, the anterograde tract
tracers cascade-blue-labeled dextran amine [cascade blue (CB)]
or biotinylated dextran amine (BDA) (both 10,000 MW; Molecu-
lar Probes, Eugene, OR, USA) were injected into the ipsilesional
or contralesional motor cortices, respectively, at 42 dpi or 42 days
post-sham surgery (Reitmeir et al., 2011, 2012). Ten days later (i.e.,
at 52 dpi), animals were sacrificed by transcardiac perfusion with
4% paraformaldehyde (Figure S1C in Supplementary Material).
The last set of mice was exposed to 30 min of MCAO followed
by 3, 14, 28, or 42 days reperfusion or to sham-surgery followed
by 3 days reperfusion (n= 4 animals/group) (Kilic et al., 2008).
Animals were sacrificed by transcardiac perfusion with 0.9% NaCl.
Brains were used for Western blot analysis of HMG-CoA reductase
abundance (Figure S1D in Supplementary Material).
Animals were always randomly attributed to experimental
groups in a blinded manner. Experimenters analyzing the data
were blinded for experimental conditions.
INDUCTION OF FOCAL CEREBRAL ISCHEMIA
Animals were anesthetized with 1% isoflurane (30% O2, remain-
der N2O). Rectal temperature was maintained between 36.5 and
37.0°C using a feedback-controlled heating system. During the
experiments, cerebral blood flow was measured by laser Doppler
flow (LDF) recordings using a flexible 0.5 mm fiberoptic probe
(Perimed, Stockholm, Sweden), which was attached to the intact
skull overlying the middle cerebral artery territory (2 mm poste-
rior/6 mm lateral from bregma). LDF changes were monitored
up to 30 min after the onset of reperfusion. For intraluminal
MCAO, a midline neck incision was made, and the left com-
mon and external carotid arteries were isolated and ligated. A
microvascular clip (FE691; Aesculap, Tuttlingen, Germany) was
temporarily placed on the internal carotid artery. A 8-0 nylon
monofilament (Ethilon; Ethicon, Norderstedt, Germany) coated
with silicon resin (Xantopren; Bayer Dental, Osaka, Japan; diam-
eter of the coated filament: 180–190µm) was introduced through
a small incision into the common carotid artery and advanced
9 mm distal to the carotid bifurcation for MCAO. Thirty min-
utes later, reperfusion was initiated by filament removal. In
sham-operated animals, a surgical intervention was performed,
in which the neck was opened and the common carotid artery
was exposed, but left intact, while LDF recordings were per-
formed. After the surgery, wounds were carefully sutured, anes-
thesia was discontinued and animals were placed back into their
cages.
Animals belonging to animal sets one to three (see Experi-
mental Groups and Interventions) were reanesthetized with 1%
isoflurane at 72 h post-ischemia. Cannula (Brain infusion kit 3;
Alzet, Cupertino, CA, USA) were implanted into the left lat-
eral ventricle (0.0 mm from bregma, 0.8 mm lateral to midline,
1.4 mm below brain surface), which were linked to miniosmotic
pumps (Alzet 2004; Alzet), which were randomly filled with vehi-
cle (0.9% NaCl) or rosuvastatin (sc-208316; Santa Cruz, Hei-
delberg, Germany; 0.2 or 2 mg/kg/day diluted in 0.9% NaCl)
and which were placed on the animals backs. These pumps
were left in place during the subsequent 4 weeks and then
removed.
Animals belonging to animal set three (see Experimental
Groups and Interventions) were reanesthetized with 1% isoflu-
rane at 42 dpi or 42 days post-sham surgery. The anterograde tract
tracers CB and BDA [both 10,000 MW; 10% dilutions in 0.01 M
phosphate-buffered saline (PBS) at pH 7.2; Molecular Probes,
Eugene, OR, USA] were injected into the ipsilesional or con-
tralesional motor cortices, respectively, by means of microsyringe
injections, as previously reported (Reitmeir et al., 2011, 2012). As
such, a total volume of 2.1µl tracer was administered to each ani-
mal, which was injected in three equal deposits located rostrally,
medially, and caudally of the needle insertion site into the motor
cortex. For this purpose, the needle was inclined 45°, 90°, and 135°
against the midline and 45° against the brain surface (needle inser-
tion for all three deposits: 0.5 mm rostral to bregma/2.5 mm lateral
to midline; injection ~0.8 mm below brain surface) (Reitmeir et al.,
2012, 2011).
FUNCTIONAL NEUROLOGICAL TESTS
Neurological recovery was assessed using grip strength, RotaRod,
open field, elevated O maze, and light/dark tests at baseline and on
days 7, 14, 28, and 42 after MCAO (Kilic et al., 2008, 2010; Reitmeir
et al., 2011).
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Grip strength test
The grip strength test consists of a spring balance coupled with
a Newtonmeter (Medio-Line Spring Scale, metric, 300 g, Pesola,
Switzerland) that is attached to a triangular steel wire, which the
animal instinctively grasps. When pulled by the tail, the animal
exerts force on the steel wire (Kilic et al., 2010). Grip strength was
evaluated at the right paretic forepaw, the left non-paretic forepaw
being wrapped with adhesive tape. Grip strength was evaluated
five times on occasion of each test, for which mean values were
calculated. From these data, percentage values (post-ischemic vs.
pre-ischemic) were computed. Pre-ischemic results did not differ
between groups.
RotaRod test
The RotaRod is a rotating drum with a speed accelerating from 6
to 40 rpm (model 47600; Ugo Basile, Comerio, Italy), which allows
to assess motor coordination skills (Kilic et al., 2010). Maximum
speed is reached after 245 s, and the time at which the animal drops
off the drum is evaluated (maximum testing time: 300 s). Measure-
ments were performed five times each on the same occasion when
grip strength was evaluated. For all five measurements, mean val-
ues were computed, from which percentage values (post-ischemic
vs. pre-ischemic) were calculated. Pre-ischemic data did not differ
between groups.
Open field test
The open field is a round arena (diameter: 150 cm) covered by a
white plastic floor, surrounded by a 35 cm high sidewall made of
white polypropylene, which allows to measure spontaneous loco-
motor activity and exploration behavior (Kilic et al., 2008). The
arena is divided into three sections, including an outer wall zone
(17.7% of diameter, close to the wall), an intermediate transition
zone (32.3% of diameter), and an inner zone (50% of diameter,
the center of the arena). Each mouse was released near the wall and
observed for 10 min. Animal paths were tracked with an electronic
imaging system (Ethovision XT6; Noldus Information Technol-
ogy, Wageningen, Netherlands), acquiring data at a frequency of
4.2 Hz with a spatial resolution of 576× 768 pixels. Raw data were
transferred to the wintrack 2.4 software for offline analysis. To
determine measures of exploratory behavior and anxiety, the time
resting and progressing, and the time spent in each of the three
zones were assessed.
Elevated O maze
The elevated O maze consists of a round 5.5 cm wide polyvinyl-
chloride runway with an outer diameter of 46 cm, which is placed
40 cm above the floor and measures correlates of fear and anxiety
(Reitmeir et al., 2011). Two opposing 90° sectors are protected
by 16 cm high inner and outer walls made of polyvinyl-chloride
(closed sectors). The remaining two 90° sectors are not protected
by walls (open sectors). Each mouse was released in one of the
open sectors and observed for 10 min. Animal paths were again
tracked with an electronic imaging system (Ethovision XT6). The
time spent in the unprotected sector was measured whenever the
animal entered this sector with all four paws.
Light/dark transition test
The light/dark transition test (40 cm× 20 cm× 20 cm) consists
of two equal light and dark chambers, which are separated by a
divider with a 4 cm× 4 cm opening at the floor level. Each mouse
was placed in the corner of the light chamber at distance from
the dark chamber and monitored for 10 min. Animal paths were
tracked with an electronic imaging system (Ethovision XT6). The
time spent in the light chamber was evaluated and presented.
IMMUNOHISTOCHEMICAL ANALYSIS OF BRAIN REMODELING
Conventional immunohistochemistry
For conventional immunohistochemistry, 20µm coronal sections
were obtained at the level of the bregma (i.e., midstriatum) from
animals that had been transcardially perfused with 0.9% NaCl at
42 dpi. After immersion fixation in 4% paraformaldehyde in 0.1 M
PBS, sections were pre-treated for antigen retrieval with 0.01 M
citrate buffer (pH 5.0), rinsed and immersed for 1 h in 0.1 M PBS
containing 0.3% Triton X-100 (PBS-T) and 10% normal donkey
serum. Sections were incubated overnight at 4°C with monoclonal
mouse anti-NeuN (MAB377; Chemicon) and monoclonal rat
anti-CD31 (#557355; BD Biosciences) antibodies (diluted 1:100
in 0.1 M PBS) that were detected with Cy3- or Cy2-conjugated
secondary antibodies. Sections were finally incubated with 4′-6-
diamidino-2-phenylindole (DAPI). In some experiments, primary
antibodies were recognized by biotinylated secondary antibodies
that were detected using an avidin–biotin kit (Vector Labora-
tories, Burlingame, CA, USA) by 3,3′-diaminobenzidine (DAB)
staining. Sections were evaluated under a fluorescence microscope
(Olympus BX41) connected to a CCD camera (CC12; Olympus).
Surviving NeuN+ neurons and CD31+ microvessels were ana-
lyzed in a blinded way by counting numbers of cells or profiles in
six defined regions of interests (ROI) in each striatum both ipsilat-
eral and contralateral to the stroke (250µm× 250µm) (Kilic et al.,
2006), for which mean values were calculated. With these measure-
ments, neuronal survival and capillary density were determined.
Stereometric analysis of post-ischemic striatum and corpus callo-
sum atrophy was done using brain sections stained with modified
Bielschowsky’s silver solution, as previously described (Reitmeir
et al., 2011).
Computer-based stereological analysis and brain volumetry
For stereological analysis of brain remodeling and brain volume-
try, 20µm coronal sections were obtained from six equidistant
brain levels, 250µm apart, of animals that had been transcar-
dially perfused with 4% paraformaldehyde in 0.1 M PBS at 42 dpi.
Sections were pre-treated for antigen retrieval with 0.01 M cit-
rate buffer (pH 5.0), rinsed and immersed for 1 h in 0.1 M
PBS-T and 10% normal donkey serum. Sections were incu-
bated overnight at 4°C with Alexa Fluor 488-conjugated mono-
clonal mouse anti-NeuN (Mab377X; Chemicon), polyclonal rab-
bit anti-CD31 (ab28364; Abcam), and Alexa Fluor 555-conjugated
monoclonal mouse anti-GFAP (#3656; Cell Signaling) antibodies
(diluted 1:100 in 0.1 PBS) that – in case of the non-conjugated anti-
body – was detected with Alexa Fluor 488-conjugated secondary
antibody (A21206; Invitrogen). Sections were finally incubated
with DAPI.
Sections were analyzed using a confocal Zeiss LSM 780 micro-
scope. A software-controlled motorized stage provided accurate
and fine movements for the x-, y-, and z-axes. In order not to miss
any cell nuclei, the focus was adjusted from top to bottom for each
slice. When the first nuclei were detected in the focus, the z-axis was
Frontiers in Cellular Neuroscience www.frontiersin.org December 2014 | Volume 8 | Article 422 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kilic et al. HMG-CoA reductase inhibition promotes post-ischemic brain plasticity
determined as top point and when last nuclei were lost in the focus,
the z-axis was determined as bottom point. For each slice, the dis-
tance between the top and bottom was ~16µm, which was divided
into four focal planes and all images were further processed as a
multiple intensity projection using Zen Black software to obtain
sharp images. Using tile and z-stack functions of the motorized
stage, all signals from NeuN+, CD31+, and GFAP+ cells in the
striatum were detected using the GaAsP detector of the micro-
scope. A single investigator analyzed all data in a blinded manner.
Mean numbers of NeuN+ cells were analyzed in the ischemic
and contralesional striatum. By dividing results obtained in both
hemispheres, the percentage of surviving neurons in the ischemic
striatum was determined. CD31+ microvessels were counted in
the entire ipsilateral striatum. With the data obtained, the mean
capillary number was calculated. In case of GFAP stainings, the
area of scar tissue was outlined using the Zen Blue software (ver-
sion 2012; Carl Zeiss). With all areas from various brain levels,
the scar volume in cubic millimeter was calculated. For brain vol-
umetry, sections collected throughout the forebrain at 250µm
intervals were stained with cresyl violet. On each section, the ipsile-
sional striatum and ipsilesional corpus callosum (that included the
external capsule) were outlined using the Zen Blue software. By
integrating areas measured across the brain, striatum, and corpus
callosum volumes in cubic millimeter were determined.
IMMUNOHISTOCHEMISTRY FOR CB AND BDA
Brain sections of animals that had transcardially been perfused
with paraformaldehyde were rinsed three times for 10 min each in
50 mM Tris-buffered saline (pH 8.0) containing 0.5% Triton X-100
(TBS-T). For detection of CB, sections were immersed overnight
at 4°C with polyclonal rabbit anti-cascade blue antibody (A-5760;
Molecular Probes, 1:100), diluted 1:100 in 50 mM TBS-T, followed
by incubation for 1 h at room temperature with a horseradish
peroxidase-labeled secondary antibody (1:1000). For detection
of BDA, sections were incubated overnight with avidin–biotin–
peroxidase complex (ABC Elite; Vector Laboratories), followed by
DAB staining.
ANALYSIS OF CORTICORUBRAL PROJECTIONS
To account for variabilities in tracer uptake in different mice, we
first evaluated the number of tracer-stained fibers in the pyra-
midal tract at the level of the parvocellular red nucleus (bregma
−3.0 to−3.5 mm). For this purpose, two consecutive sections were
analyzed, counting the number of fibers crossing the sections in
four regions of interest of 2865µm2 each that had been selected
in the dorsolateral, ventrolateral, dorsomedial, and ventromedial
portion of the pyramidal tract. By measuring the total area of the
pyramidal tract using the Cell Software image system (Olympus)
connected to an Olympus BX42 microscope, we calculated the
overall number of labeled pyramidal tract fibers (Z’Graggen et al.,
1998; Reitmeir et al., 2011).
For evaluation of midline-crossing fibers, a 500µm long-
intersection line was superimposed on the brain midline. Along
that line those fibers crossing into the contralateral hemisphere
in direction of the red nucleus were quantified. For each animal
and both tracers, the total number of fibers counted was normal-
ized with the total number of labeled fibers in the pyramidal tract,
as determined for each tracer. This value was multiplied by 100,
resulting in percent values of fibers crossing the midline. For both
tracers always two consecutive sections were analyzed, of which
mean values were determined.
WESTERN BLOTTING
Tissue samples were collected from both middle cerebral artery
territories of animals sacrificed by transcardiac perfusion with
0.9% NaCl (Reitmeir et al., 2011). Following sodium dodecyl
sulphate–polyacrylamide gel electrophoresis, polyvinylidene flu-
oride membranes were incubated with rabbit polyclonal HMG-
CoA reductase antibody (Ab98018; Abcam, Cambridge, UK) that
was detected by chemiluminescence labeling. Protein loading was
controlled using a β-actin antibody. Protein abundance was eval-
uated by densitometry. Three independent blots were analyzed.
For these blots, mean values were calculated, which were normal-
ized with optical densities determined in corresponding samples
of sham-operated mice.
STATISTICAL ANALYSIS
Neurological tests were evaluated by means of two-way repeated
measurement analysis of variance (ANOVA) for all four time-
points starting at 7 days post-stroke, i.e., the first examination
after MCAO had been induced. For those tests, in which sig-
nificant treatment or treatment by time interaction effects were
noticed,post hoc comparisons were performed for each time-point
using unpaired t -tests with Bonferroni corrections. Western blot-
ting and histochemical data were evaluated by one-way ANOVA
followed by least significant differences tests (comparison between
≥3 groups) or unpaired t -tests (comparisons between 2 groups).
p-Values<0.05 were considered significant.
RESULTS
POST-ACUTE DELIVERY OF ROSUVASTATIN IMPROVES POST-ISCHEMIC
NEUROLOGICAL RECOVERY
To evaluate if the HMG-CoA reductase inhibitor rosuvastatin
influences neurological recovery, mice submitted to 30 min of
MCAO were intraventricularly treated with vehicle or rosuvas-
tastin (2 or 0.2 mg/kg/day) starting at 3 dpi, i.e., at a time-point,
at which acute ischemic injury has already evolved (Reitmeir
et al., 2011, 2012). LDF, which was recorded above the core of
the middle cerebral artery territory using a flexible fiberoptic
probe that was attached to the animals’ skulls, did not show any
differences between groups. In all experimental conditions, LDF
decreased to ~15–20% of baseline during MCAO, followed by a
rapid restoration of blood flow after reperfusion (Figure 1A).
Significant reductions of motor force of the contralesional right
forepaw (Figure 1B) and motor coordination skills (Figure 1C)
were detected in ischemic mice, as shown in grip strength and
RotaRod tests. In vehicle-treated mice and in mice receiving rosu-
vastatin at the low dosage (0.2 mg/kg/day), grip strength, and
coordination skills largely remained unchanged over the obser-
vation period of 42 days (Figures 1B,C). In animals treated with
rosuvastatin at the higher dosage (2 mg/kg/day), progressive recov-
ery of grip strength and motor coordination were observed,
resulting in robust and significant improvement starting at 14 dpi
(Figures 1B,C).
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FIGURE 1 | Delayed delivery of rosuvastatin at a dose of 2mg/kg/day,
but not 0.2mg/kg/day, promotes post-ischemic recovery of grip
strength and motor coordination. (A) Laser Doppler flow (LDF)
recordings above the core of the middle cerebral artery territory, (B) grip
strength of the lesion-contralateral right paretic forepaw, and (C) motor
coordination evaluated by RotaRod tests of ischemic mice treated with
vehicle or rosuvastatin (0.2 or 2 mg/kg/day i.c.v.) starting at 72 h
post-ischemia. Note that motor force (B) and coordination skills (C), which
are compromised following stroke, do not exhibit any major improvements
over time in vehicle-treated mice and mice receiving rosuvastatin at a
dosage of 0.2 mg/kg/day, but progressively improve over 14–42 days in
animals treated with rosuvastatin at a 2 mg/kg/day dosage. LDF
measurements (A), which were recorded for evaluating the reproducibility
of ischemia, do not differ between groups. BL, baseline. Data are mean
values±SD (n=20 animals/group). **p<0.01/*p<0.05 for high-dose
rosuvastatin (2.0 mg/kg/day) compared with ischemic vehicle; §p<0.05 for
low-dose rosuvastatin (0.2 mg/kg/day) compared with ischemic vehicle.
Whereas overall locomotor activity that was reduced by MCAO
was mildly increased by rosuvastatin, as shown in open field
tests (Figure 2A), rosuvastatin decreased the time spent in the
open field wall zone (Figure 2B) and increased the time spent
in the open field transition zone (Figure 2C) and center zone
(Figure 2D), indicating partial reversal of an anxious phenotype
that was induced by the stroke. In line with this promotion of
exploration behavior, the time spent in the unprotected zone of
the elevated O maze (Figure 2E) and the time spent in the light
zone of the light/dark transition test (Figure 2F) were significantly
increased by rosuvastatin at a 2 mg/kg/day dosage. In view that
effects on grip strength and coordination skills were noticed only
when the higher dose of rosuvastatin was administered, the lat-
ter studies and all following studies were performed only in mice
receiving vehicle or 2 mg/kg/day rosuvastatin.
ROSUVASTATIN PROMOTES PERI-LESIONAL TISSUE REMODELING
To clarify how the post-acute rosuvastatin delivery modifies
the remodeling of ischemic brain tissue, we used two differ-
ent approaches, i.e., conventional histochemical analysis and
computer-based stereology and volumetry, always with consis-
tent results in two different sets of mice. Rosuvastatin at a dose
of 2 mg/kg/day significantly increased neuronal survival after the
observation period of 42 days (Figure 3A; Figure S2A in Supple-
mentary Material), preventing striatum (Figure 3B; Figure S2B in
Supplementary Material) and corpus callosum (Figure 3C; Figure
S2C in Supplementary Material) atrophy. Brain capillary density
was increased in the lesion-sided striatum of rosuvastatin-treated
as compared with vehicle-treated ischemic mice (Figure 3D;
Figure S2D in Supplementary Material),but not the overlying pari-
etal cortex (not shown). Glial scar formation was slightly reduced
by rosuvastatin (1.76± 0.64 vs. 1.44± 0.60 mm3 in vehicle-treated
compared with rosuvastatin-treated animals); yet, this effect failed
significance.
ROSUVASTATIN PROMOTES CONTRALESIONAL CORTICORUBRAL
TRACT PLASTICITY
Since the pyramidal tract crosses the middle cerebral artery ter-
ritory, which was affected by ischemia, we examined how rosu-
vastatin influences pyramidal tract degeneration and plasticity.
We administered two dextran conjugates, CB and BDA, into
both motor cortices (Figure 4A). The analysis of injection sites
revealed no relevant differences between groups. In all animals,
injection sites covered the more caudal forelimb area and ros-
tral hindlimb area of the primary motor cortex without relevant
spreading of tracer deposits into subcortical structures. The size
of the pyramidal tract, evaluated as area covered by the cerebral
peduncle in coronal brain sections, was slightly lower in the ipsile-
sional ischemic, as compared to non-ischemic pyramidal tract,
but was not influenced by rosuvastatin (10.8± 3.5 mm2 in non-
ischemic vehicle,8.0± 1.8 mm2 in ischemic vehicle,8.0± 2.3 mm2
in ischemic rosuvastatin; p< 0.05 for ischemic rosuvastatin and
ischemic vehicle compared with non-ischemic vehicle).
Cascade blue- and BDA-stained fibers originating from the
cerebral peduncle turned dorsomedially at mesencephalic levels,
terminating as previously described in the parvocellular part of
the ipsilateral red nucleus (Figure 4A) (Reitmeir et al., 2011).
At this level, we quantified both the number of fibers crossing
through the pyramidal tract and the number of fibers branch-
ing off the pyramidal tract and migrating across the midline in
direction to the red nucleus in the other hemisphere. Our studies
revealed that MCAO increased the number of CB-labeled fibers
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FIGURE 2 | Delayed delivery of rosuvastatin promotes post-ischemic
spontaneous exploration behavior, thus, reducing anxiety. (A)Time
progressing, (B) time spent in the wall zone, (C) time spent in the
transition zone, and (D) time spent in the core zone of the open field test,
as well as (E) time spent in the unprotected zone of the elevated O maze
and (F) time spent in the light zone of the light/dark transition test of
ischemic mice treated with vehicle or rosuvastatin (2 mg/kg/day i.c.v.)
starting at 72 h post-ischemia. Note that while overall motor activity does
not differ between groups (A), exploration activities of ischemic mice in
the transition zone (C), and core zone (D) of the open field are increased
by rosuvastatin. Furthermore, note that the time spent in the unprotected
zone of the elevated O maze (E) and the time spent in the light zone of
the light/dark test (F) are increased by rosuvastatin, indicating that
post-stroke anxiety is attenuated by HMG-CoA reductase inhibition BL,
baseline. Data are mean values±SD (n=20 animals/group).
**p<0.01/*p<0.05 compared with ischemic vehicle.
in the ipsilesional cerebral peduncle, whereas rosuvastatin deliv-
ery did not further elevate this number (19171± 6026 CB-labeled
fibers in non-ischemic vehicle, 35942± 19114 CB-labeled fibers
in ischemic vehicle, 38425± 11567 CB-labeled fibers in ischemic
rosuvastatin;p< 0.01 for ischemic rosuvastatin and ischemic vehi-
cle compared with non-ischemic vehicle). Conversely, neither
MCAO nor rosuvastatin influenced the number of labeled fibers in
the contralesional cerebral peduncle (48300± 19429 BDA-labeled
fibers in non-ischemic vehicle, 55944± 17875 BDA-labeled fibers
in ischemic vehicle, 55988± 14028 BDA-labeled fibers in ischemic
rosuvastatin; n.s.). Hence, rosuvastatin did not induce the de novo
formation of proximal axons, neither ipsilateral nor contralateral
to the stroke.
The percentage of midline-crossing fibers derived from the
lesion-sided pyramidal tract, as revealed by CB, increased (though
not significantly) upon MCAO (Figures 4B,D), whereas the
percentage of BDA-labeled midline-crossing fibers originating
from the contralesional pyramidal tract remained unchanged
(Figures 4C,D). Importantly, rosuvastatin significantly increased
the percentage of midline-crossing fibers originating from the
BDA-labeled contralesional pyramidal tract, without influencing
the percentage of CB-labeled ipsilesional pyramidal tract fibers
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FIGURE 3 | Rosuvastatin promotes peri-lesional tissue remodeling.
(A) Surviving neurons in ischemic striatum evaluated by NeuN
immunohistochemistry, (B) striatum atrophy, and (C) corpus callosum atrophy
examined by cresyl violet stainings, and (D) capillary number in the ischemic
striatum assessed by CD31 immunohistochemistry at 42 dpi in ischemic mice
receiving vehicle or rosuvastatin (2 mg/kg/day i.c.v.) starting at 72 h
post-ischemia. Data were analyzed using an investigator-independent
computer-based stereology and volumetry approach. Note that rosuvastatin
increases neuronal survival (A), diminishes progressive brain atrophy (B,C),
and increases capillary survival (D). Representative microphotographs are
also shown. Data are mean values±SD (n=10 animals/group). *p<0.05
compared with ischemic vehicle. Bars, 1000µm (A–D).
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FIGURE 4 | Rosuvastatin promotes contralesional corticorubral
plasticity. Tract tracing analysis of corticorubral projections ipsilateral and
contralateral to the stroke in mice receiving cascade blue (CB) and
biotinylated dextran amine (BDA) injections into the lesion-sided and
contralesional motor cortex [for experimental procedures see (A)]. Percent
of midline-crossing fibers to (B) the contralesional red nucleus (RN) traced
by CB and (C) ipsilesional red nucleus traced by BDA. Note that the
percentage of midline-crossing fibers after ipsilesional CB injection
increases in response to stroke (though not significantly) (B). Importantly,
rosuvastatin, delivered at a dose of 2 mg/kg/day, does not further elevate the
percentage of midline-crossing fibers originating from the ipsilesional
pyramidal tract (B), but increases the percentage of contralesional pyramidal
tract fibers growing out across the midline in direction to the ipsilesional red
nucleus (C). (D) Microphotographs of representative vehicle-treated and
rosuvastatin-treated ischemic mice illustrating BDA traced corticorubral
fibers crossing the midline in between both red nuclei. Note that the
ipsilesional (left) red nucleus receives more BDA traced fibers after
rosuvastatin than vehicle delivery. Data are mean values±SD (n=10
animals/group). §p<0.05 compared with non-ischemic vehicle; *p<0.05
compared with ischemic vehicle. Bar, 100µm.
(Figures 4B–D). Thus, rosuvastatin enhanced the sprouting of ter-
minal fibers originating from the contralateral, but not ipsilateral
motor cortex.
HMG-CoA REDUCTASE IS UPREGULATED IN THE CONTRALESIONAL
HEMISPHERE
Based on the observation that HMG-CoA reductase inhibition
enhanced contralesional pyramidal tract plasticity, we finally ana-
lyzed how focal cerebral ischemia influences HMG-CoA reductase
abundance both ipsilateral and contralateral to the stroke. In West-
ern blots, we show that the abundance of HMG-CoA reductase
increased in the contralateral hemisphere at 14 and 28 dpi in mice
exposed to 30 min MCAO (Figure 5). In the ipsilesional hemi-
sphere, HMG-CoA reductase abundance transiently decreased at
3 dpi.
DISCUSSION
We herein show that post-acute delivery of the HMG-CoA
reductase inhibitor rosuvastatin, initiated at 72 h post-ischemia,
that is a time-point far beyond classical neuroprotection, pro-
motes neurological recovery, peri-lesional tissue remodeling, and
contralesional pyramidal tract plasticity in mice submitted to
MCAO. Robust correlates of recovery of motor function, coor-
dination skills, and exporation behavior were noticed in func-
tional neurological tests that were accompanied by decreased
neuronal degeneration and brain atrophy, and increased cap-
illary survival. Contralateral to the stroke, enhanced sprout-
ing of midline-crossing motor cortical fibers was induced by
rosuvastatin, providing another structural correlate for the
improved neurological recovery.
The observation of increased axonal plasticity in response to
HMG-CoA reductase inhibitor delivery that occurs at distance to
the lesion is new. It has previously been shown that HMG-CoA
reductase inhibition promotes post-ischemic neuronal survival in
the acute stroke phase (Sironi et al., 2003; Kilic et al., 2005), inhibit
brain inflammation (Pahan et al., 1997; Kilic et al., 2005), restore
endothelial function (Endres et al., 1998; Amin-Hanjani et al.,
2001), and promote angiogenesis and neurogenesis (Chen et al.,
2003). Following exposure of primary cortical neurons that had
undergone oxygen–glucose deprivation to the HMG-CoA reduc-
tase inhibitor simvastatin, increased neurite outgrowth has been
reported, which was made responsible for the increased remod-
eling of Bielschowsky-labeled fiber tracts along the lesion border
that was found by the same authors in simvastatin treated rats
subjected to 2 h MCAO (Cui et al., 2012). These observations
in the vicinity of the stroke lesion are in line with our findings
of reduced striatum and corpus callosum atrophy. That corpus
callosum atrophy is reduced by HMG-CoA reductase inhibition
has to the best of our knowledge not yet been shown. Mech-
anistically, neuronal plasticity induced by HMG-CoA reductase
inhibitors is thought to be mediated by prevention of geranyl-
geranylation, as previously shown in vitro in rat hippocampal
neurons, in which inhibition of geranylgeranylation mimicked
effects of the HMG-CoA reductase inhibitor pravastatin on neuri-
togenesis (Pooler et al., 2006). Pravastatin significantly decreased
levels of membrane-associated RhoA, suggesting that reduced
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FIGURE 5 | HMG-CoA reductase abundance in the ischemic and
contralesional hemisphere. Western blot analysis of the ~100 kDa
double band of HMG-CoA reductase at various reperfusions times
following 30 min MCAO. Representative blots are also shown. Note the
upregulation of HMG-CoA reductase in the contralesional hemisphere at
14 and 28 d.p.i. Data are mean values±SD (n=3 independent
blots/group). §§p<0.01/§p<0.05 compared with corresponding samples
from sham-operated mice.
geranylgeranylation of RhoA, which is required for membrane
binding, was responsible (Pooler et al., 2006).
Studies in different models of MCAO using antibodies directed
against axonal growth inhibitors [e.g., Nogo-A (Papadopoulos
et al., 2002; Wiessner et al., 2003)], pleiotropic growth factors
[e.g., erythropoietin, vascular endothelial growth factor (Reitmeir
et al., 2011, 2012)], and neural precursor/stem cells (Andres et al.,
2011) have in the meantime shown that contralesional pyrami-
dal tract plasticity is a structural correlate of recovery in a variety
of neurorestorative therapies. The present study shows that the
HMG-CoA reductase inhibitor rosuvastatin shares this property.
In contrast to antibodies, growth factors, and cell-based therapeu-
tics, HMG-CoA reductase inhibitors may systemically be deliv-
ered without major side effects or complications. Unfortunately,
HMG-CoA reductase inhibitors that are clinically used today are
highly hydrophilic drugs, which poorly cross the blood–brain bar-
rier. In order to ensure the brain access of rosuvastatin, which
may still hamper in the post-ischemic brain despite blood–brain
barrier opening, we used an i.c.v. delivery strategy and adminis-
tered an effective drug dosage that was approximately an order of
magnitude higher than that prescribed in human patients.
Since HMG-CoA reductase inhibitors are genuine pharmaco-
logical compounds that in contrast to growth factors, antibodies,
or cells can easily be administered in stroke patients without
concerns, more lipophilic HMG-CoA reductase inhibitors, which
are able to enter the brain, might be useful neuronal plasticity-
promoting drugs. Besides, HMG-CoA reductase inhibitors have
very favorable effects on post-ischemic angiogenesis (Chen et al.,
2003), which make them promising for restorative stroke therapy.
We used a model of transient focal cerebral ischemia, in which
the pyramidal tract is injured, while the motor cortex, which
is located outside the middle cerebral artery territory, remains
intact. Additional studies using a model, resulting in motor cortical
infarcts (e.g., photothrombotic stroke) as well as studies using
systemic HMG-CoA reductase inhibitor delivery may be valu-
able, before the translational potential of HMG-CoA reductase
inhibitor-induced neuronal plasticity may finally be evaluated.
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